vzphotos AbbVie (NYSE:ABBV) said Wednesday it plans on reporting acquired IPR&D and milestone expenses of $937M on a pre-tax basis for Q2, which will reduce earnings per share on both a GAAP and non-GAAP basis by $0.52. In an SEC filing, AbbVie said it now sees reporting Q2 adjusted EPSContinue Reading
vzphotos/iStock Editorial via Getty Images Cerevel Therapeutics (NASDAQ:CERE) quickly fell 4% amid a report about the Federal Trade Commission’s review of its sale to AbbVie. The staff of the FTC’s Mergers 1 section is said to be apparently considering a recommendation to block the Cerevel (CERE) deal, according to aContinue Reading
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) named Robert A. Michael as the CEO and joined AbbVie’s Board of Directors, effective today. Mr. Michael succeeds Richard A. Gonzalez, who has served as CEO since the company’s inception in 2013. Mr. Gonzalez has become executive chairman of the board of directors.Continue Reading
Genmab (GMAB) and partner AbbVie (NYSE:ABBV) have received U.S. FDA approval for their monoclonal antibody Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma. The approval is based on results from Phase 1/2 EPCORE NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients withContinue Reading
vzphotos/iStock Editorial via Getty Images Cerevel Therapeutics (NASDAQ:CERE) fell 5.5% as investors wait to hear if the Federal Trade Commission will approve its planned $8.7 billion sale to AbbVie (NYSE:ABBV). The deal spread is the widest since the transaction was announced in early December. While there was no specific reasonContinue Reading
AbbVie’s (NYSE:ABBV) new drug application for its Parkinson’s disease combination therapy has been denied approval by the FDA. In a complete response letter sent to the drugmaker, the U.S. drug regulator cited observations that were identified during inspection of a third-party manufacturer listed in the application. The inspection at theContinue Reading
